Eli Lilly and Company v. Medtronic, Inc., 496 U.S. 661 (1990), is a United States Supreme Court case related to patent infringement in the medical device industry. It held that 35 U.S.C. § 271(e)(1)[1] of United States patent law exempted premarketing activity conducted to gain approval of a device under the Federal Food, Drug, and Cosmetic Act from a finding of infringement.[2]

See also

References

  1. ^ 35 U.S.C. § 271(e)(1).
  2. ^ Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).

External links